Shanghai Argo Entered into Collaboration Agreements on Multi-Program RNAi Licenses with Novartis

SHANGHAI, China, January 07, 2024- Argo Biopharma announced that it entered into two exclusive license and collaboration agreements with Novartis PHARM AG ("Novartis") on January 07. 2024.

Argo Biopharma receives upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. And Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worldwide exclusive license for a Phase 1 stage cardiovascular asset and an option to license compounds directed against up to two cardiovascular targets.

For details, please click: https://www.argobiopharma.com/news/103.html